{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hu X"],"funding":["National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Instit","National Institute for Health Research (NIHR)","National Natural Science Foundation of China","China Postdoctoral Science Foundation","National Institute for Health and Care Research","National Key Research and Development Program of China"],"pagination":["104333"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9646865"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["86"],"pubmed_abstract":["<h4>Background</h4>Targeting helper T cells, especially Th17 cells, has become a plausible therapy for many autoimmune diseases.<h4>Methods</h4>Using an in vitro culture system, we screened an epigenetics compound library for inhibitors of IFN-γ and IL-17 expression in murine Th1 and Th17 cultures.<h4>Findings</h4>This identified IOX1 as an effective suppressor of IL-17 expression in both murine and human CD4<sup>+</sup> T cells. Furthermore, we found that IOX1 suppresses Il17a expression directly by targeting TET2 activity on its promoter in Th17 cells. Using established pre-clinical models of intraocular inflammation, treatment with IOX1 in vivo reduced the migration/infiltration of Th17 cells into the site of inflammation and tissue damage.<h4>Interpretation</h4>These results provide ev"],"journal":["EBioMedicine"],"pubmed_title":["Epigenetic drug screen identified IOX1 as an inhibitor of Th17-mediated inflammation through targeting TET2."],"pmcid":["PMC9646865"],"funding_grant_id":["2021M700776","20221373","82171041","2021YFA1101200","81900844","2021YFA1101204"],"pubmed_authors":["Yuan S","Wen X","Lait PJP","Lee RWJ","Copland DA","Zhou P","Hu X","Stimpson M","Guo S","Schewitz-Bowers LP","Dick AD","Zou Y","Liu Y","Li Y","Li S","Zhang Z","Liang J","Li JJ","Wei L","Chen T"],"additional_accession":[]},"is_claimable":false,"name":"Epigenetic drug screen identified IOX1 as an inhibitor of Th17-mediated inflammation through targeting TET2.","description":"<h4>Background</h4>Targeting helper T cells, especially Th17 cells, has become a plausible therapy for many autoimmune diseases.<h4>Methods</h4>Using an in vitro culture system, we screened an epigenetics compound library for inhibitors of IFN-γ and IL-17 expression in murine Th1 and Th17 cultures.<h4>Findings</h4>This identified IOX1 as an effective suppressor of IL-17 expression in both murine and human CD4<sup>+</sup> T cells. Furthermore, we found that IOX1 suppresses Il17a expression directly by targeting TET2 activity on its promoter in Th17 cells. Using established pre-clinical models of intraocular inflammation, treatment with IOX1 in vivo reduced the migration/infiltration of Th17 cells into the site of inflammation and tissue damage.<h4>Interpretation</h4>These results provide ev","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-05T12:31:36.473Z","creation":"2024-11-05T22:00:33.709Z"},"accession":"S-EPMC9646865","cross_references":{"pubmed":["36335665"],"doi":["10.1016/j.ebiom.2022.104333"]}}